MEETING NOTES OF THE
ADHB CHARITABLE TRUST RESEARCH GRANTS COMMITTEE MEETING
HELD MONDAY 24, APRIL, 2007
ROOM 534, ADMIN SUITE, LEVEL 5
AUCKLAND CITY HOSPITAL, GRAFTON
Commenced at 4.00 pm
All minutes of this meeting are subject to ratification at the next RGC meeting as a result of a quorum not being
present.
Present:
In Attendance:
Roger Jarrold
Janet Latimer
Richard Frith (Chair)
Colin McArthur
David St George
David Sage
Ralph Stewart
Gayl Humphrey (ex Officio)
Apologies:
Tut Than
1 Minutes of Previous Meeting
Resolved
That the minutes of the A+ Trust Research Grants Committee meeting Monday 10 April 2007 be
approved by the members and confirmed as a true and accurate record of that meeting.
Moved: Richard Frith
Seconded: Roger Jarrold
2 Matters Arising
Projects from previous meeting:
3546 – Carry forward from RGC meeting 10 April 2007, a review of the budget has been requested as
drugs provided at no charge therefore costs should be excluded from the budget, which will then be in
surplus. Vernon Harvey to review & revise.
3761 – Carry forward from RGC meeting 10 April 2007, David Knight to submit applications for funding
support to A+ Trust cover research costs of $18,500.
Meeting Notes of A+ Trust Research Grants Committee Meeting held Monday, 23 April 2007
3 Projects Reviewed
Proj #
3621
PI and Title
Budget
John Kolbe
Yes
Status
Approved
Project has been approved
A Phase 3, Open-Label,
by the RRC. Concerns were
Follow-On
Study
Of
raised
Courses
Of
issues arising out of projects
Aztreonam Lysinate For
returning large surpluses.
Inhalation (AI) In Cystic
The trial will terminate if the
Fibrosis
drug becomes commercially
Multiple
Patients
(AIR-
CF3) CP-AI-006
3629
Comments
probity
available.
Jocelyn Benatar
Yes
DORADO-AC
Optimized
regarding
Approved
–
Doses
The project is an add-on to
current
of
standard
care
treatment. Project will return
Darusentan as Compared
a significant surplus.
to an Active Control in
Resistant Hypertension
A Phase 3 Randomised,
Double-Blind,
and
Placebo-
Active-Controlled,
Multi-centre,
Parallel
Group Study to Evaluate
the Safety and Efficacy
of
Darusentan
in
Subjects with Resistant
Hypertension
Receiving
Combination
with
Therapy
Three
or
Antihypertensive
More
Drugs,
Including a Diuretic, as
Compared to Guanfacine
or Placebo
3688
Shay McGuiness. Early
parental
nutrition
Yes
Approved
Project will return a surplus.
Yes
Approved
Project will return a surplus.
vs.
standard care in critical
illness:
an
investigator
led level I randomised
RCT
3695
Ernie
Willoughby
A
Randomized, Multicenter,
Double-Blind,
Placebo-
Controlled,
Dose
-
Comparison
Study
to
Determine
the
Safety
andResearch
EfficacyGrants
of BG00012
Meeting Notes of A+ Trust
Committee Meeting held Monday, 23 April 2007
in
Subjects
Relapsing
with
Remitting
Multiple Sclerosis.
Proj #
3696
PI and Title
Budget
Peter Browett: A Phase II Study
Status
No
of MK-0457 in Patients with BCRABL
T3151
Mutant
Not
Project has been submitted on behalf
approved
of Uniservices, However as it relates
Chronic
to patient care it should be an ADHB
and
project. Request will be made to PI to
Philadelphia Chrmosome -positive
submit a project budget and project
Acute Lymphoblastic Leukaemia.
ownership will remain with ADHB.
Myelogenous
3709
Sue
Leukaemia
Stott
Of
CT
Determination
Of
increase should additional CT scans
Screw Position After Percutaneous
be required, but these costs will be
Screw Fixation Of Slipped Capital
fully recovered from the University of
Scanning
The
In
Role
Yes
Approved
Femoral Epiphysis
3736
Protocol
There is a potential for a cost
Auckland.
Richard Doocey.
Use
Compassionate
RRC receiving
used and how they generate a
Blood Stem Cells for Collection and
drug
Transplantation
savings
De
Mobilise
Boer:
The
A
of
Approval subject to
total
Determine
Use
Approved
Peripheral
Sally
the
–
additional information on drugs being
to
for
Yes
claiming
AMD3100
3745
Comments
Study
To
Relationship
Of
Yes
from
savings for ADHB.
Approved
application being made to the A+
Exercise Intolerance And Dyspnoea
To
Clinical
Function
Appearances
Features,
Trust MG Martin fund
Pulmonary
Parameters,
And
Approval is given subject to funding
HRCT
Psychological
Factors In Sarcoidosis
3771
Colin McArthur
Yes
Approved
Small deficit which will be internally
Atorvastatin treatment in severe
funded from the DCCM accumulated
infection
funds.
Meeting Notes of A+ Trust Research Grants Committee Meeting held Monday, 23 April 2007
4 Draft Savings Policy
The draft savings policy is on the SMT agenda and will be discussed as time permits.
5 Financial Update
5.1
Monthly status report
Reports from 10 April meeting have been included for information only
5.2
Monthly reimbursements
Reports from 10 April meeting have been included for information only
5.3
Conversion of research projects to A+ Trust
Target completion date remains 30 June 2007.
5.4
Applications for A+ Trust general funds to support Research
Project 3284 – Research Nurse 0.2 FTE UoA salary funding. Budget top up has been approved
using A+ trust fund 7554.
6 General Business
6.1
Project report tabled from David Herd for information only.
6.2
Meeting times will be moved up by 30 minutes so meeting will now commence at 3.30 pm.
Meting concluded 5.10 pm
…………………………………………
Chair
Next Meeting:
Venue:
………………………………………
Date
Monday, 28th May 2007 at 3:30 pm
Room 534, Admin Suite, Level 5, Auckland City Hospital, Grafton
Meeting Notes of A+ Trust Research Grants Committee Meeting held Monday, 23 April 2007